Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418298 | 0.89 | SLC9A1 (0.45) | NR4A2MAP4K4RAB9ASLC9A1RXRA | |
| SCHEMBL419611 | 0.82 | ALOX5 (0.47) | SHMT1RAB9AGABRA2GABRB2POLB | |
| SCHEMBL2485562 | 0.81 | MAPK14 (0.38) | NR4A2MAPK14SHMT1MAP4K4SLC9A1 | |
| SCHEMBL421725 | 0.76 | NPC1 (0.44) | MAP4K4RAB9ASLC9A1RXRARXRB | |
| SCHEMBL421281 | 0.76 | PDE4B (0.41) | RAB9ACHRM1 | |
| SCHEMBL420175 | 0.74 | PTGDR2 (0.40) | NR4A1NR4A2NR4A3 | |
| SCHEMBL421353 | 0.73 | MCL1 (0.44) | NR4A2RAB9ASLC9A1RXRARXRB | |
| SCHEMBL2487648 | 0.73 | ALOX5 (0.41) | SHMT1CHRM1 | |
| SCHEMBL16438509 | 0.72 | DCLRE1B (0.51) | MAPK14MAP4K4RAB9ADCLRE1BCHRM1 | |
| SCHEMBL421473 | 0.70 | ALOX5 (0.56) | RAB9AGABRA2GABRB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2376479-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | NR4A1 2488/4885NR4A2 1704/4885NR4A3 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.